{"nctId":"NCT04248868","briefTitle":"tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden","startDateStruct":{"date":"2020-06-23","type":"ACTUAL"},"conditions":["Pulmonary Embolism"],"count":109,"armGroups":[{"label":"BEC Treatment","type":"EXPERIMENTAL","interventionNames":["Device: The Bashir™ Endovascular Catheter","Drug: r-tPA"]}],"interventions":[{"name":"The Bashir™ Endovascular Catheter","otherNames":[]},{"name":"r-tPA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Willing and able to provide informed consent;\n2. Age 18 to ≤ 75 years of age;\n3. PE symptom duration ≤ 14 days.\n4. Filling defect in at least one main or lobar pulmonary artery as determined by contrast enhanced chest CT (CTA);\n5. RV/LV diameter ratio ≥ 0.9 by CTA as determined by the investigative site;\n6. Willing and able to comply with all study procedures and follow-up.\n\nExclusion Criteria:\n\n1. CVA or TIA within one (1) year;\n2. Head trauma, active intracranial, or intraspinal disease ≤ one (1) year prior to inclusion in the study;\n3. Active bleeding from a major organ within one (1) month prior to inclusion in the study;\n4. Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms, arteriovenous malformations, or aneurysms);\n5. Patients with bleeding diatheses;\n6. Hematocrit \\< 30%;\n7. Platelets \\< 100,000/μL;\n8. INR \\> 1.5 if currently on warfarin (Coumadin®);\n9. aPTT \\> 50 seconds in the absence of anticoagulants;\n10. Major surgery ≤ 14 days prior to inclusion in the study;\n11. Serum creatinine \\> 2.0mg/dL;\n12. Clinician deems high-risk for catastrophic bleeding;\n13. History of heparin-induced thrombocytopenia (HIT Syndrome);\n14. Pregnancy;\n15. SBP \\< 90 mmHg \\> 15 minutes within two (2) hours prior to BEC procedure and is not resolved with IV fluids;\n16. Any vasopressor support;\n17. Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and/or referring institution;\n18. Evidence of irreversible neurological compromise;\n19. Life expectancy \\< one (1) year;\n20. Use of thrombolytics or glycoprotein IIb/IIIa inhibitor within 3 days prior to inclusion in the study;\n21. Use of non-vitamin K oral anti-coagulants (NOACs), such as rivaroxaban (Xarelto®), apixaban (Eliquis®), dabigatran (Pradaxa®), edoxaban (Savaysa®) within 48 hours prior to inclusion in the study;\n22. Profound bradycardia requiring a temporary pacemaker and/or inotropic support;\n23. Previous enrollment in this study;\n24. Morbidly obese patient who by the judgement of the investigator is high risk for bleeding;\n25. BMI \\> 45kg/m2;\n26. Absolute contraindication to anticoagulation;\n27. Uncontrolled hypertension defined as SBP \\> 175mmHg and / or DBP \\> 110mmHg with pharmacotherapy within two (2) hours prior to inclusion in the study;\n28. Currently participating in another study;\n29. Any arterial line placement;\n30. Current positive COVID diagnosis, or ≤ 8 weeks negative of COVID, or \\> 8 weeks from positive COVID test and with current symptoms, or current active viral pneumonia on chest CT scan;\n31. In the opinion of the investigator, the subject is not a suitable candidate for the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy: RV/LV Ratio Difference","description":"Observe RV/LV diameter ratio difference between baseline and 48 hours after the completion of r-tPA treatment as measured by contrast enhanced chest CT (CTA).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety: Major Bleeding","description":"Major Bleeding as defined by International Society of Thrombosis and Hemostasis (ISTH), within 72 hours of initiation of r-tPA administration. Bleeding criteria are as follows: Major Bleeding in Non-Surgical Patients\n\n1. Fatal bleeding; and/or\n2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome; and/or\n3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more or leading to transfusion of two or more units of whole blood or red cells.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":109},"commonTop":["Arrhythmia","Apnoeic attack","Device operational issue","Insomnia","Electrolyte imbalance"]}}}